tetano
Editor, Senior Moderator
Clin Infect Dis
. 2020 Dec 14;ciaa1846.
doi: 10.1093/cid/ciaa1846. Online ahead of print.
Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting
Laith J Abu-Raddad[SUP] 1 2 3 [/SUP], Hiam Chemaitelly[SUP] 1 2 [/SUP], Joel A Malek[SUP] 4 5 [/SUP], Ayeda A Ahmed[SUP] 4 [/SUP], Yasmin A Mohamoud[SUP] 4 [/SUP], Shameem Younuskunju[SUP] 4 [/SUP], Houssein H Ayoub[SUP] 6 [/SUP], Zaina Al Kanaani[SUP] 7 [/SUP], Abdullatif Al Khal[SUP] 7 [/SUP], Einas Al Kuwari[SUP] 7 [/SUP], Adeel A Butt[SUP] 7 [/SUP], Peter Coyle[SUP] 7 [/SUP], Andrew Jeremijenko[SUP] 7 [/SUP], Anvar Hassan Kaleeckal[SUP] 7 [/SUP], Ali Nizar Latif[SUP] 7 [/SUP], Riyazuddin Mohammad Shaik[SUP] 7 [/SUP], Hanan F Abdul Rahim[SUP] 8 [/SUP], Hadi M Yassine[SUP] 9 10 [/SUP], Mohamed G Al Kuwari[SUP] 11 [/SUP], Hamad Eid Al Romaihi[SUP] 12 [/SUP], Mohamed H Al-Thani[SUP] 12 [/SUP], Roberto Bertollini[SUP] 12 [/SUP]
Affiliations
Abstract
Background: Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirmed cases in Qatar.
Methods: All SARS-CoV-2 laboratory-confirmed cases with at least one PCR positive swab that is ≥45 days after a first-positive swab were individually investigated for evidence of reinfection, and classified as showing strong, good, some, or weak/no evidence for reinfection. Viral genome sequencing of the paired first-positive and reinfection viral specimens was conducted to confirm reinfection. Risk and incidence rate of reinfection were estimated.
Results: Out of 133,266 laboratory-confirmed SARS-CoV-2 cases, 243 persons (0.18%) had at least one subsequent positive swab ≥45 days after the first-positive swab. Of these, 54 cases (22.2%) had strong or good evidence for reinfection. Median time between first and reinfection swab was 64.5 days (range: 45-129). Twenty-three of the 54 cases (42.6%) were diagnosed at a health facility suggesting presence of symptoms, while 31 (57.4%) were identified incidentally through random testing campaigns/surveys or contact tracing. Only one person was hospitalized at time of reinfection, but was discharged the next day. No deaths were recorded. Viral genome sequencing confirmed four reinfections out of 12 cases with available genetic evidence. Reinfection risk was estimated at 0.02% (95% CI: 0.01-0.02%) and reinfection incidence rate at 0.36 (95% CI: 0.28-0.47) per 10,000 person-weeks.
Conclusions: SARS-CoV-2 reinfection can occur but is a rare phenomenon suggestive of protective immunity against reinfection that lasts for at least a few months post primary infection.
Keywords: SARS-CoV-2; epidemiology; genetics; immunity; reinfection.
. 2020 Dec 14;ciaa1846.
doi: 10.1093/cid/ciaa1846. Online ahead of print.
Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting
Laith J Abu-Raddad[SUP] 1 2 3 [/SUP], Hiam Chemaitelly[SUP] 1 2 [/SUP], Joel A Malek[SUP] 4 5 [/SUP], Ayeda A Ahmed[SUP] 4 [/SUP], Yasmin A Mohamoud[SUP] 4 [/SUP], Shameem Younuskunju[SUP] 4 [/SUP], Houssein H Ayoub[SUP] 6 [/SUP], Zaina Al Kanaani[SUP] 7 [/SUP], Abdullatif Al Khal[SUP] 7 [/SUP], Einas Al Kuwari[SUP] 7 [/SUP], Adeel A Butt[SUP] 7 [/SUP], Peter Coyle[SUP] 7 [/SUP], Andrew Jeremijenko[SUP] 7 [/SUP], Anvar Hassan Kaleeckal[SUP] 7 [/SUP], Ali Nizar Latif[SUP] 7 [/SUP], Riyazuddin Mohammad Shaik[SUP] 7 [/SUP], Hanan F Abdul Rahim[SUP] 8 [/SUP], Hadi M Yassine[SUP] 9 10 [/SUP], Mohamed G Al Kuwari[SUP] 11 [/SUP], Hamad Eid Al Romaihi[SUP] 12 [/SUP], Mohamed H Al-Thani[SUP] 12 [/SUP], Roberto Bertollini[SUP] 12 [/SUP]
Affiliations
- PMID: 33315061
- DOI: 10.1093/cid/ciaa1846
Abstract
Background: Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirmed cases in Qatar.
Methods: All SARS-CoV-2 laboratory-confirmed cases with at least one PCR positive swab that is ≥45 days after a first-positive swab were individually investigated for evidence of reinfection, and classified as showing strong, good, some, or weak/no evidence for reinfection. Viral genome sequencing of the paired first-positive and reinfection viral specimens was conducted to confirm reinfection. Risk and incidence rate of reinfection were estimated.
Results: Out of 133,266 laboratory-confirmed SARS-CoV-2 cases, 243 persons (0.18%) had at least one subsequent positive swab ≥45 days after the first-positive swab. Of these, 54 cases (22.2%) had strong or good evidence for reinfection. Median time between first and reinfection swab was 64.5 days (range: 45-129). Twenty-three of the 54 cases (42.6%) were diagnosed at a health facility suggesting presence of symptoms, while 31 (57.4%) were identified incidentally through random testing campaigns/surveys or contact tracing. Only one person was hospitalized at time of reinfection, but was discharged the next day. No deaths were recorded. Viral genome sequencing confirmed four reinfections out of 12 cases with available genetic evidence. Reinfection risk was estimated at 0.02% (95% CI: 0.01-0.02%) and reinfection incidence rate at 0.36 (95% CI: 0.28-0.47) per 10,000 person-weeks.
Conclusions: SARS-CoV-2 reinfection can occur but is a rare phenomenon suggestive of protective immunity against reinfection that lasts for at least a few months post primary infection.
Keywords: SARS-CoV-2; epidemiology; genetics; immunity; reinfection.